Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Doxil in Relapsed/Refractory AML
NCT01736943Phase 2Completed
- Start
- Dec 2012
- Primary completion
- May 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in acute myeloid leukemia (AML). Started Dec 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01736943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736943.